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Abstract
Kawasaki disease (KD) is an acute febrile illness of childhood 
of unknown origin which may cause coronary arteritis and death. 
The Maltese incidence has been calculated at 3.2/100,000 
population ≤ 4 years of age, similar to that reported in European 
communities and far lower than that reported in Asian countries. 
The use of steroids in this condition remains contentious. We 
report a resistant case of KD who required two doses of pulsed 
steroids in addition to standard treatment with aspirin and 
immunoglobulin.
Introduction
Kawasaki disease (KD), formerly known as mucocutaneous 
lymph node syndrome, is an acute febrile illness of childhood 
of unknown origin. The underlying pathology is an arteritis 
involving small and medium sized arteries. Diagnosis is based on 
clinical criteria which include conjunctivitis, oral manifestations, 
polymorphous rash, and swelling of the peripheries which is 
followed by peeling. The most severe complication is coronary 
arteritis, which may lead to aneurysm formation, and the 
eventual formation of coronary artery strictures. The frequency 
of this complication has decreased from 25% to 2-3% with the 
availability of treatment which involves high dose, intravenous 
γ-globulin and high dose aspirin. 
We report our first immunoglobulin resistant case of KD 
who required treatment with two doses of pulsed steroids. We 
also extend the results of an earlier study which had shown 
the annual number of cases of KD.1 With regard to incidence, 
the catchment area for this study was Malta. Cases of KD were 
identified from computerised ward admission records for the 
period 1992 to date.
Case summary
Our patient presented with a 4 day history of fever up to 
104°F, nonpurulent conjunctivitis and a maculopapular rash on 
the thighs, shins and extensor surfaces of the forearms. He was 
being followed up regularly at Children’s Outpatients for a small 
ventricular septal defect. By the following day, the rash had spread 
to the face. The suspicion of sepsis due to a high white blood cell 
count led to commencement of ceftriaxone (Table 2). 24 hours 
later, he also developed mucositis and swelling of the hands and 
feet with palmar erythema, and a diagnosis of Kawasaki disease 
was made. He was administered intravenous immunoglobulin 
(IVIG) 2g/kg, started on high dose aspirin (25mg/kg/6h) and the 
fever dropped to 99-100ºF. Despite normal renal function tests, 
he became oliguric with normal urinalysis and microscopy, was 
catheterised and intravenous fluids were increased. No effusions 
were noted on echocardiography and the coronary arteries were 
normal (Figure 1). On day 8 of the acute illness, the rash on the 
lower limbs started to fade and the ceftriaxone was stopped. 
Several boluses of fluids and frusemide were administered over the 
next few days as the oliguria persisted. He still had low grade fever 
(99-100°F), but aspirin had to be stopped as he started passing 
melaena. A second course of high dose immunoglobulins was 
administered together with regular ranitidine and frusemide. A 
repeat echocardiogram only showed good cardiac function, a small 
pericardial effusion and trivial mitral and tricuspid regurgitation 
that had not been noted before. He became hypoalbumenaemic 
and was given 20% albumin (LFTs otherwise normal) and was 
restarted on antibiotics (cefotaxime) in view of the persistently 
high WBC count. A transfusion was also given due to a dropping 
haemoglobin (Table 1, day 9). He subsequently developed gross 
abdominal distension, and a greenish nasogastric aspirate due to 
a combination of ascites and ileus secondary to hypokalaemia. 
A surgical review advised the addition of omeprazole as the 
stools had remained dark and tarry in consistency. Due to the 
concern with regard to the possibility of endocarditis, on day 12, 
the antibiotics were changed to teicoplanin and meropenem 
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and an albumin infusion was repeated. Some peeling of the 
extremeties was noted over the next few days. As the patient’s 
general condition improved, the rash faded, and the mucositis 
cleared, aspirin was restarted, and the antibiotics were stopped 
as cultures had remained negative throughout. On day 24, 
diffuse coronary artery dilatation (Figure 1) concomitant with 
a rise in temperature prompted the administration of pulsed 
methylprednisolone 400mg daily. He remained afebrile 
over the next 3 days and was discharged on aspirin 300mg 
6 hourly (100mg/kg/day) and omeprazole 20mg daily. After 
4 days, he was readmitted in view of increasing inflammatory 
indices and persistent low grade fever (day 38 in Table 1). 
Methylprednisolone 400mg daily, was readministered for 3 days 
and he was again discharged on aspirin and omeprazole. Since 
discharge he has remained afebrile and well. His blood count and 
c-reactive protein levels were monitored at each visit as shown 
in Table 1. Coronary dilatation slowly improved on subsequent 
echos and no aneurysms were seen. Interestingly, the platelet 
count only rose and persisted above 400×109/l by day 20, after 
the second dose of steroids.
Kawasaki disease in Malta
The annual number of patients with KD is shown in Table 2. 
The incidence has remained static since our previous study.1
Discussion
The rate of KD in Malta remains similar to rates reported 
for European populations,2,3 and much less than that reported 
in purely Asiatic populations (Table 2).4 
Accelerated matrix breakdown caused by the increased 
activity of matrix metalloproteinases (MMPs) and/or the 
quantitative imbalance between MMP and tissue inhibitor 
of MMP (TIMP) have been implicated in the destruction of 
the coronary arterial wall and the resultant coronary arterial 
lesions in Kawasaki disease.5 The blockade of plasminogen 
activators prevents the formation of aneurysms and arterial 
rupture by inhibiting MMP activation. High dose intravenous 
gammaglobulins (IVIG) combined with oral aspirin, to reduce 
inflammation in the coronary arterial wall, has become the 
standard treatment during the acute phase of Kawasaki 
Table 2: Annual cases of KD extended 
from a previous publication (rate 
3.2/100,000 population < 5 years 
of age for the period 1992-1997)1
Year Annual cases
1992 2
1993 0
1994 2
1995 1
1996 1
1997 4
1998 1
1999 0
2000 0
2001 0
2002 1
2003 3
2004 0
2005 4
2006 1
Table 1: Patient indices 
Day Hb (g/dl) WBC (x109/l) Plt (x109/l) CRP (u/l)
 4 11 19.4 284
  7 9.5 33.3 190 304
 9 8.1 33 151 186
 11 12.4 26.3 129 147
 13 11.3 23.1 212 116
 17 10.1 11.8 356 70
 20 9.8 7.03 489 45
 23 8.4 7.98 477 162
 28 7.5 12.7 448 179
 31 12.2 9.72 491 31
 38 12.4 14.7 417 187
 46 12.4 25.5 583 67
 52 12.3 17.6 610 6
Figure 1: Top left; normal right coronary artery. 
Top right; normal left coronary artery. Bottom right; 
dilated right coronary artery origin. Bottom left; 
dilated left coronary artery and branches (left anterior 
descending indicated by cursor)
Malta Medical Journal    Volume 20   Issue 04   December 2007 2
disease. The efficacy of IVIG in preventing coronary artery 
lesions may therefore be related to protection against arterial 
wall destruction via reduction of cytokine induced MMP 
stimulation. Some Kawasaki disease patients that have been 
administered high dose IVIG continue to suffer from coronary 
artery aneurysms. Corticosteroids have been proposed as an 
effective treatment for Kawasaki disease and several recent 
studies suggest that corticosteroid therapy can be effective.5 The 
potent anti-inflammatory effects of steroids are well established, 
and these include the suppression of inflammatory cytokines 
and a direct inhibitory effect on MMP activation. Steroids are 
now primarily used to treat Kawasaki disease patients who are 
unresponsive to IVIG therapy. However, studies have shown 
that initial treatment with combined high dose IVIG and 
corticosteroids is more effective in the prevention of coronary 
artery lesions than the use of IVIG or steroids on their own but 
more detailed studies with double blind placebo control are 
required.6
Our current practice is to administer high dose IVIG at 
diagnosis and introduce pulsed methylprednisolone only if 
the disease remains active. The earlier introduction of steroids 
may be justified if poor prognostic factors for coronary artery 
lesions, such as excessive fluid retention or hypoalbumenaemia 
are present.7
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Corinthia Group Prize in Paediatrics, 2007
For the first time since its inception, the Corinthia Group 
Prize in Paediatrics was awarded jointly to Dr Rodianne 
Vassallo and Dr Daniel Cauchi, who both obtained the same 
top aggregate mark over the combined examinations in 
Paediatrics in the fourth and final year of the undergraduate 
course. As always, competition for the Corinthia Group Prize 
was as stiff as ever, with ten candidates vying for the honour 
and a tie for the top spot!  Whilst offering our congratulations 
to Dr Rodianne Vassallo and Dr Daniel Cauchi, we would also 
like to congratulate all those undergraduates (now doctors) 
who performed admirably during the undergraduate course 
in Paediatrics. In the accompanying photograph, Dr Vassallo 
and Dr Cauchi are seen receiving their (shared) cheque for 
Lm50 each from Professor Simon Attard Montalto, Head 
of Paediatrics at the Medical School. Finally, the Academic 
Department of Paediatrics and Medical School remain 
indebted and are extremely grateful to the Corinthia Group 
for their ongoing support.
Professor Simon Attard Montalto
